mild cognitive impairment
Conditions
Interventions
The patients of active drug group will be intervened with 6 tablets of Sea-alpa every-day for 1 year.
The patients with placebo group will be intervened with 6 tablets of placebo every-day for 1 year.
Sponsors
Department of Neuropsychiatry, Institute of Clinical Medicine University of Tsukuba
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Outpatients with MCI of the department of Neuropsychiatry, University hospital of Tsukuba. 2) Being able to give a written informed consent to the participation in the present study. 3) Being able to observe the following requirements: good compliance with Sea-alpa; participation in the schedules examinations for assessment; keeping log-diary recording consumption of Sea-alpa. 4) Having a modified Hachinski Ischemic score of 4 or less. 5) Having the 15-item Geriatric Depression Scale score of 6 or less.
Exclusion criteria
Exclusion criteria: 1) Meeting DSM-IV TR criteria for dementing illnesses. 2) Having serious or unstable illnesses. 3) Having a history within past 5 years of serious infections disease affecting the brain and/or malignant diseases. 4) Having a history of alcohol or drug abuse or dependence (on DSM-IVTR) within the past 5 years. 5) Receiving any types of anti-Alzheimer drugs. 6) Recent (within 4 weeks) initiation of medications that affect the central nervous system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score in Japanese version of ADAS-Cog and Mini Mental State Examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Scores in Japanese version of ADCS-ADL, Geriatric Depression Scale. | — |
Countries
Japan
Contacts
Public ContactTakashi Asada
University of Tsukuba Department of Neuropsychiatry, Institute of Clinical Medicine
Outcome results
None listed